Upadacitinib in atopic dermatitis: additional benefit for adults at high dose

IQWiG

1 December 2021 - Women should expect more serious adverse effects than men. 

For children and adolescents and for the lower dose, an additional clinical benefit has not been proven in the absence of suitable study data.

Read IQWiG press release [German]

Michael Wonder

Posted by:

Michael Wonder